How Genetic Testing Results Impact Breast Cancer Treatment: Allison Kurian, MD, MSc

​With our ever-growing understanding of mutations that increase cancer risk and the rise of targeted treatments such as poly (ADP-ribose) polymerase (PARP) inhibitors that are indicated for specific mutations, the use of germline genetic testing for patients with breast cancer has increased significantly in recent years. How are these test results affecting patients' treatment? In a population-based cohort study published recently published in JAMA Oncology, Allison W. Kurian, MD, MSc, and colle...

Continue reading

Advanced Breast Cancer: Adding Abemaciclib to Fulvestrant Improves Survival

​Updated results from MONARCH 2 report that adding abemaciclib (Verzenio®, Eli Lilly) to fulvestrant (Faslodex®, AstraZeneca) improves overall survival compared with fulvestrant alone in patients with endocrine-refractory hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. "Most patients with metastatic breast cancer have tumors that are HR-positive and are initially treated with endocrine therapy. Although endocrine therapy is an effi...

Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2022 Oncology Data Advisor. All rights reserved.